Press Releases

- Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals' lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML - WALTHAM, Mass. , Jan. 30, 2020 /PRNewswire/ --  Syndax Pharmaceuticals, Inc.

- Final OS analysis for pivotal Phase 3 E2112 trial in HR+, HER2- breast cancer expected 2Q20 - - Phase 1 data presentation from AUGMENT-101 trial of SNDX-5613 in acute leukemias expected 4Q20; potential for interim results throughout 2020- - SNDX-6352 Phase 2 expansion trial in cGVHD initiated;

- Preliminary Phase 1 results demonstrate inhibition of CSF1R leads to responses in patients with cGvHD - - Phase 2 expansion expected to commence in 1Q20 - WALTHAM, Mass. , Dec. 10, 2019 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical

- Data provide detailed look at potential underlying mechanism of action within cells - - Results support ongoing development of SNDX-5613, Company's lead highly selective Menin inhibitor, for treatment of MLL-rearranged acute leukemias - WALTHAM, Mass. , Dec.

- E2112 trial passed final interim OS analysis; trial continues, with final OS analysis expected in 2Q20 - - First patient dosed in Phase 1/2 AUGMENT-101 trial of SNDX-5613, Company's highly selective Menin inhibitor, for treatment of MLL-rearranged acute leukemias and NPM1-mutant AML - - Company

- Company expects to report initial clinical data in 2020 - WALTHAM, Mass. , Nov. 6, 2019 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced

WALTHAM, Mass. , Oct. 31, 2019 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2019 financial

WALTHAM, Mass. , Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in four

- IND cleared for SNDX-5613, highly selective menin inhibitor for treatment of MLL-rearranged and NPM1-mutant acute leukemias - - Final interim OS analysis for E2112 expected in 4Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. , Aug.

WALTHAM, Mass. , Aug. 5, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W.

WALTHAM, Mass. , July 31, 2019 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2019 financial

-- SNDX-5613 is a potent, highly selective, oral inhibitor of the interaction of Menin with the Mixed Lineage Leukemia (MLL) protein -- -- Strong tumor growth inhibition and improved survival observed in preclinical models -- WALTHAM, Mass. , July 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals,